We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Sagimet Biosciences Inc (SGMT) USD0.0001 A

Sell:$4.50 Buy:$4.60 Change: $0.13 (2.93%)
Market closed |  Prices as at close on 9 May 2024 | Switch to live prices |
Sell:$4.50
Buy:$4.60
Change: $0.13 (2.93%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 9 May 2024 | Switch to live prices |
Sell:$4.50
Buy:$4.60
Change: $0.13 (2.93%)
Market closed |  Prices as at close on 9 May 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.

Contact details

Address:
155 BOVET RD., SUITE 303
SAN MATEO
94402
United States
Telephone:
+1 (650) 5618600
Website:
https://sagimet.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SGMT
ISIN:
US7867001049
Market cap:
$138.19 million
Shares in issue:
31.92 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • David Happel
    President, Chief Executive Officer, Director
  • Thierry Chauche
    Chief Financial Officer
  • Anthony Rimac
    Chief Operating Officer
  • Elizabeth Rozek
    Chief Compliance Officer, General Counsel
  • Eduardo Martins
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.